H.C. Wainwright says the bar is set for oral GLP-1s following this morning’s type 2 diabetes data from Eli Lilly (LLY). The firm continues to expect Viking Therapeutics (VKTX) to “differentiate” with its dual GLP-1/GIP asset VK2735. The data collected in the Phase 1 assessing oral VK2735 is at 28 days exhibited up to an 8.2% reduction in body weight was observed, and oral VK2735 maintained excellent tolerability profile through 100 mg dose level with 99% of adverse events being mild to moderate, the analyst tells investors in a research note. H.C. Wainwright believes Viking’s oral formulation of VK2735 “remains differentiated in the space” in terms of mechanism, efficacy, and safety. It keeps a Buy rating on Viking shares with a $102 price target. The stock in midday trading is down 2% to $23.22.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Eli Lilly jumps as results from weight-loss pill study rival competitor’s
- JPMorgan says Lilly data ‘highly favorable’ for Structure Therapeutics
- Viking Therapeutics slips after Eli Lilly reports orforglipron trial results
- Viking Therapeutics’ VK2735: A Promising Contender Amidst Pfizer’s Setback
- Promising Pipeline and Strategic Developments Drive Buy Rating for Viking Therapeutics
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue